This guideline provides updated, localized recommendations for the rapid diagnosis, risk stratification, and comprehensive management of NSTE-ACS in Taiwan.
Answers are grounded in this paper and cite their sources.
Standardizes NSTE-ACS care in Taiwan; extends international evidence with localized recommendations.
In Taiwan, the incidence of non-ST segment elevation acute coronary syndrome (NSTE-ACS) continues to increase in recent years. The purpose of this guideline is to help health care professionals in Taiwan to use adequate tests and treatments for management of NSTE-ACS. For rapid diagnosis, in addition to history and physical examination, 0/3 h rapid diagnosis protocol with high sensitivity cardiac troponin assay is recommended in this guideline. Dual antiplatelet and anticoagulation therapies are important parts in the initial treatment. Risk stratification should be performed to identify high risk patients for early coronary angiography. Through evaluation of the coronary anatomy and other clinical factors, the decision for coronary revascularization, either by percutaneous coronary intervention or coronary artery bypass grafting, should be decided by the heart team. The duration of dual antiplatelet therapy should be given for at least 12 months after discharge. Other secondary preventive medications are also recommended for long term use.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) conducted a review in non ST-segment elevation acute coronary syndrome (NSTE-ACS). Management guidelines for NSTE-ACS was evaluated. The 2018 Taiwan guidelines for NSTE-ACS recommend a 0/3 h rapid diagnosis protocol with high sensitivity cardiac troponin, dual antiplatelet and anticoagulation therapies, and risk stratification.
Synapse has enriched 10 related papers. Consider them for comparative context: